Aethlon Medical Inc (AEMD)

[Tahoe2468]

Investorideas.com has released a two-part series on virus treatment developments, featuring Aethlon Medical's (NASDAQ: AEMD) Hemopurifier®. The Hemopurifier® is a breakthrough device for cancer and viral disease treatment, recognized by the FDA. Recent updates include phase 1 clinical trials for cancer patients who are unresponsive to anti-PD-1 therapy. The device has shown potential in treating various viruses in vitro, including HIV, Ebola, and H5N1 bird flu. Zacks reported rising vaccine stocks due to growing bird flu threats. Other companies like ImmunityBio and Aligos Therapeutics are also advancing in viral treatments. This news follows WHO's alert on a new H5N2 bird flu strain causing a human death in Mexico.

Positive
Aethlon Hemopurifier® designated as a 'Breakthrough Device' by the FDA.
Phase 1 clinical trials planned for cancer patients using Hemopurifier®.
In vitro success of Hemopurifier® against multiple viruses, including HIV, Ebola, and H5N1.
Zacks reports rising vaccine stocks due to bird flu threats.
ImmunityBio's promising preclinical data for HIV treatment with N-803 and bNAbs.
Aligos Therapeutics reports positive antiviral and safety data at EASL Congress.